CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading compound profile…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Cannabinoids/WIN 55212-2

Synthetic cannabinoids

WIN 55212-2

A organic heterotricyclic compound that is 5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-<em>hi</em>]indole substituted at position 6 by a 1-naphthylcarbonyl group.

Definition: CHEBI:73295 · Chemical Entities of Biological Interest · release 253

(2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone[(3R)-5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanoneWin 55,212WIN 55212-2

81public articles

9registered condition areas

All documents →

Identity & provenance

Chemical identity

C27H26N2O3 · molecular weight 426.516

CAS: cas:131543-22-1↗CHEBI: CHEBI:73295↗INCHI: InChI=1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3/t20-/m1/s1↗INCHIKEY: HQVHOQAKMCMIIM-HXUWFJFHSA-N↗LINCS.SMALLMOLECULE: lincs.smallmolecule:LSM-15494↗PATENT: patent:US2002182159↗PATENT: patent:US2003049220↗PATENT: patent:US2010215759↗PUBCHEM_CID: 5311501↗PUBMED: pubmed:14512703↗PUBMED: pubmed:15888960↗PUBMED: pubmed:17306870↗PUBMED: pubmed:19883712↗PUBMED: pubmed:20158615↗PUBMED: pubmed:20307280↗PUBMED: pubmed:20969930↗PUBMED: pubmed:21055447↗PUBMED: pubmed:21057002↗PUBMED: pubmed:21091643↗PUBMED: pubmed:21130785↗

Sources: ChEBI · 253 PubChem computed properties · pug-b8d00227e38690b6

0 referenced plant-occurrence records. They are identity candidates, not clinical evidence.

Research areas

Conditions found alongside this compound

Document links and organism occurrence are candidates, not proof of efficacy, safety or a treatment recommendation.

Epilepsy and cannabinoids

7 matching public articles

Candidate association · not a treatment claim

Chronic pain and cannabinoids

1 matching public articles

Candidate association · not a treatment claim

Multiple sclerosis and cannabinoids

1 matching public articles

Candidate association · not a treatment claim

Parkinson disease and cannabinoids

2 matching public articles

Candidate association · not a treatment claim

Alzheimer disease and cannabinoids

3 matching public articles

Candidate association · not a treatment claim

Post-traumatic stress disorder and cannabinoids

2 matching public articles

Candidate association · not a treatment claim

Migraine disorders and cannabinoids

1 matching public articles

Candidate association · not a treatment claim

Inflammatory bowel diseases and cannabinoids

1 matching public articles

Candidate association · not a treatment claim

Alcohol use disorders and cannabinoids

1 matching public articles

Candidate association · not a treatment claim

Linked local records

Medicines and registered studies

Links use source-reported active ingredients or study intervention names and remain candidates, not treatment claims.

Medicines with this active ingredient

No public medicine record matched.

Registered studies

0 exact source-intervention matches.

No registered study intervention matched.

Latest documents

Recent research

2026

WIN55,212-2 attenuates intestinal fibrosis in a DSS-induced mouse model.

Pharmacological Reports · Free full text

2026

WIN 55,212-2 Modulates Antiviral, Inflammatory, and ER Stress Responses in Mayaro Virus-Infected Macrophages: Insights from RNA-Seq and In Vitro Studies.

Viruses · Free full text

2026

A Male Mouse Model of WIN 55,212-2 Self-Administration to Study Cannabinoid Addiction.

Bio-protocol · Free full text · non-commercial reuse

2026

TRP-Dependent Calcium Regulation in HCEC-12 Cells: Involvement of Ascorbic Acid and Cannabinoid Receptor Signaling.

International Journal of Molecular Sciences · Free full text

2025

Cannabinoids Activate Endoplasmic Reticulum Stress Response and Promote the Death of Avian Retinal Müller Cells in Culture.

Brain Sciences · Free full text

2025

Region-Specific Impact of Repeated Synthetic Cannabinoid Exposure and Withdrawal on Endocannabinoid Signaling, Gliosis, and Inflammatory Markers in the Prefrontal Cortex and Hippocampus.

Biomolecules · Free full text

2025

Reelin Deficiency and Synaptic Impairment in the Adolescent Prefrontal Cortex Following Initial Synthetic Cannabinoid Exposure.

Biological Psychiatry Global Open Science ·

Ontology definitions normalize terms; they do not establish medical claims.

Free full text

2025

Enhanced Cytotoxicity and Receptor Modulation by SMA-WIN 55,212-2 Micelles in Glioblastoma Cells.

International Journal of Molecular Sciences · Free full text

2025

Synthesis of Novel Chloro-Benzo [d]imidazole Regioisomers as Selective CB2 Receptor Agonists: Indirect Functional Evaluation and Molecular Insights.

Pharmaceuticals · Free full text

2025

Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models.

Translational Neurodegeneration · Free full text

2025

Modulatory Effects of CB1 Receptors on Cognitive Performance in Rat Model of Empathic Pain.

Basic and Clinical Neuroscience · Free full text · non-commercial reuse

2024

Licofelone, a Dual COX/LOX Inhibitor, Ameliorates Paclitaxel-Induced Mechanical Allodynia in Rats in a Cannabinoid Receptor-Dependent Manner.

Biomedicines · Free full text